Azacitidine Injection
Brand: AZACITIDINE
This drug is currently listed as in shortage by the FDA. Affected manufacturer: Hikma Pharmaceuticals USA, Inc..
Active FDA Drug Shortage
Contact your pharmacist if you are affected. They can check availability from other manufacturers or suggest alternatives.
Shortage Details
- Generic Name
- Azacitidine Injection
- Manufacturer
- Hikma Pharmaceuticals USA, Inc.
- Dosage Form
- Injection
- Presentation
- Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)
- Package NDC
- 0143-9606-01
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Dec 18, 2020
- Last Updated
- Mar 12, 2026
- Therapeutic Category
- Oncology
Shortage Reason
Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.
Nearby — Other Azacitidine Shortage Records
Azacitidine Injection
Meitheal Pharmaceuticals, Inc.
Injection
Azacitidine Injection
Eugia US LLC
Injection
Azacitidine Injection
Fresenius Kabi USA, LLC
Injection
Azacitidine Injection
Bristol Myers Squibb Co.
Injection
Azacitidine Injection
Accord Healthcare Inc.
Injection
Azacitidine Injection
Dr. Reddy's Laboratories, Inc.
Injection
Frequently Asked Questions
Why is Azacitidine in shortage?
What can I do if my medication is in shortage?
How often is this data updated?
What This Azacitidine Shortage Record Means
The FDA Drug Shortages database lists this record for Azacitidine Injection (brand: AZACITIDINE) from Hikma Pharmaceuticals USA, Inc. with a current status of Active Shortage. The affected dosage form is Injection, presented as Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01). Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.
This shortage was first reported on Dec 18, 2020 and was last updated Mar 12, 2026. The FDA cites the following reason: Additional lots are scheduled for manufacturing to meet demand. There are 6 other current records in this database covering the same generic, which gives a fuller picture of how disruption is playing out across manufacturers and dosage forms.
A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.
Disclaimer: This information comes from the FDA Drug Shortages Database and is for educational purposes only. It is not medical advice. Do not stop or change any medication without consulting your healthcare provider or pharmacist. Shortage status can change rapidly — always verify current availability with your pharmacist.
Read our methodology — how this data is sourced, computed, and verified.